28 unchanged sentences
Amended and Restated Bylaws of Precision BioSciences, Inc.
−Removed: Amendment No.
−Removed: 1, dated March 10, 2020, to Collaboration and License Agreement by and between Gilead Sciences, Inc.
−Removed: and Precision BioSciences, Inc., dated September 10, 2018, as amended
−Removed: Second Amendment to Lease, dated March 12, 2020, to Lease Agreement between Precision BioSciences, Inc.
+Added: Form of Indenture.
+Added: Third Amendment to Lease, dated June 15, 2020, to Lease Agreement between Precision BioSciences, Inc.
and Durham TW Alexander, LLC, dated October 2, 2018, as amended
−Removed: Eighth Amendment, dated March 3, 2020, to Lease Agreement between Precision BioSciences, Inc.
−Removed: and Venable Tenant, LLC, dated April 5, 2010, as amended
−Removed: Amendment No.
−Removed: 2, dated February 3, 2020, to the Amended and Restated Investors’ Rights Agreement among the Company and certain of its stockholders and the holders of the 2019 Notes, dated May 25, 2018, as amended
+Added: Third Amendment to the Loan and Security Agreement, dated June 23, 2020, among Precision BioSciences, Inc., Elo Life Systems, Inc.
+Added: and Pacific Western Bank.
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
19 unchanged sentences
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
+Added: August 13, 2020
/s/ Matthew Kane
1 unchanged sentence
(principal executive officer and authorized signatory)
+Added: August 13, 2020
/s/ Abid Ansari
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.